Work

Supplementary Figure S4 from Comutations and KRASG12C Inhibitor Efficacy in Advanced NSCLC

Year: 2023
Type: supplementary-materials
Abstract: Clinical outcomes with KRAS G12Ci therapy according to co-mutation status for A) KEAP1, B) SMARCA4, and C) CDKN2A in patients previously treated with immune checkpoint inhibitors.
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4379653189
Cites:
Cited by:
Related to: 10